Log in Free sign up

Karyopharm Therapeutics (KPTI) News and press releases

News

From Benzinga Pro

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK

Biotech, Large Cap, News, Penny Stocks, Health Care, Financing, Offerings, Small Cap, FDA, Insider Trades, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement

News, Penny Stocks, Small Cap, Movers, Trading Ideas

Looking Into Karyopharm Therapeutics's Return On Capital Employed

Karyopharm Therapeutics (NASDAQ:KPTI) brought in sales totaling $47.67 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 206.92%, resulting in a loss of $41.40 million.

Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting from June 3-June 7

Biotech, News, Events, General

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced promising initial data from a Phase 1/2 study evaluating selinexor in combination

Karyopharm And Menarini Group Receive Positive CHMP Opinion For Nexpovio (selinexor) For The Treatment Of Patients With Refractory Multiple Myeloma

-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy , May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a

Karyopharm Therapeutics, Menarini Group Report Positive European Medicines Agency Committee For Medicinal Products For Human Use Opinion For Their NEXPOVIO For Treatment Of Patients With Refractory Multiple Myeloma

Biotech, News, FDA, General

̶ European Commission Decision Anticipated within Approximately 60 Days – NEWTON, Mass. and FLORENCE, Italy, May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage

Analyst Ratings for Karyopharm Therapeutics

Analyst Ratings

Analysts have provided the following ratings for Karyopharm Therapeutics (NASDAQ:KPTI) within the last quarter:

SVB Leerink Maintains Market Perform on Karyopharm Therapeutics, Lowers Price Target to $5

News, Price Target, Analyst Ratings

SVB Leerink maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Market Perform and lowers the price target from $6 to $5.

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study

Biotech, Earnings, News, Penny Stocks, Health Care, Contracts, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Recap: Karyopharm Therapeutics Q1 Earnings

Karyopharm Therapeutics (NASDAQ:KPTI) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Karyopharm Therapeutics Q1 EPS $(0.53) Beats $(0.63) Estimate, Sales $47.70M Beat $34.17M Estimate

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.63) by 15.87 percent. This is a 31.17 percent increase over losses of $(0.77) per

Earnings Scheduled For May 5, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

Karyopharm Therapeutics Earnings Preview

Karyopharm Therapeutics (NASDAQ:KPTI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Karyopharm Therapeutics will report an earnings per share (EPS) of $-0.63.

Aldeyra Therapeutics CFO Joshua Reed To Resign; Bruce Greenberg Appointed Interim CFO

News, Management

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities. Mr. Reed will continue to

Press releases

From Benzinga Pro

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., July 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company approved the grant of

Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma

- Selinexor is an oral small molecule XPO1 inhibitor; tislelizumab is an anti-PD-1 checkpoint inhibitor SHANGHAI and HONG KONG, June 26, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene"

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., June 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company approved the grant of

Karyopharm to Participate at the Jefferies Healthcare Conference

NEWTON, Mass., June 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior

Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting

– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Favorable Tolerability with No Dose Limiting Toxicities and 75% of Evaluable

The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study

- Phase 3 Study Evaluating an All Oral Regimen of Selinexor in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma - ROTTERDAM, Netherlands and NEWTON, Mass.,

Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy , May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress

NEWTON, Mass., May 12, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that initial data from a Phase 1

Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference

NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior

Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – – XPOVIO® (selinexor) Net Product Revenue of $28.3 Million,

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., May 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that in connection with the hiring of

Aldeyra Therapeutics Announces Chief Financial Officer Transition

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities. Mr. Reed will continue to

Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting

NEWTON, Mass., April 27, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstracts highlighting

Karyopharm to Participate at the Canaccord Genuity Horizons in Oncology Conference

NEWTON, Mass., April 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior